Delphia Therapeutics
Joshua Sacher is an experienced professional in the field of computational chemistry and medicinal chemistry, currently serving as Associate Director of Computational Chemistry at Delphia Therapeutics since March 2024. Sacher has a diverse background, including roles as a Teaching Fellow and Course Assistant for CS50 since January 2018, and previously held positions such as Principal Scientist at Photys Therapeutics, where work focused on Phosphorylation-Inducing Chimeric Small Molecules (PHICS), and Senior Drug Discovery Scientist at Cyclica, emphasizing AI-driven drug discovery. Sacher also contributed to significant medicinal chemistry projects at the Broad Institute, along with a postdoctoral research stint at the University of Pittsburgh and a PhD from Penn State University, highlighting expertise in chemistry and biochemistry across various therapeutic domains.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.